CREBBP as a Biomarker in relapsed/refractory DLBCL

By Robert Dillard - Last Updated: October 4, 2021

A study shows that CREB binding protein (BP) inactivation may serve as robust therapeutic strategy in diffuse large B-cell lymphoma (DLBCL). The findings were published in Cancer Letters.

In this study, the researchers found chidamide, a novel histone deacetylase inhibitor, is effective in treating a subgroup of patients with relapsed/refractory DLBCL, who achieved an overall response rate of 25% and a complete response rate of 15%.

However, the clinical response to chidamide remains poor as most patients exhibited resistance, hampering the clinical utility of the drug, according to the researchers. The results showed that a combinatorial drug screening of 130 kinase inhibitors targeting cell cycle regulators identified AURKA inhibitors, which inhibit the G2/M transition during the cell cycle.

“Our study demonstrates that CREBBP inactivation can serve as a potential biomarker to predict chidamide sensitivity, while combination of an AURKA inhibitor and chidamide is a novel therapeutic strategy for the treatment of relapsed/refractory DLBCL,” the researchers concluded.

Post Tags:DLBCL